Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials

Author(s): Davide Tassinari*, Chiara Cherubini, Britt Roudnas, Emiliano Tamburini, Fabrizio Drudi, Emanuela Bianchi, Manuela Fantini, Francesco Montanari, Sergio Sartori

Journal Name: Reviews on Recent Clinical Trials

Volume 13 , Issue 3 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Introduction: To compare the efficacy of abiraterone acetate, enzalutamide, cabazitaxel and Radium-223 in the treatment of castration-resistant, docetaxel-resistant metastatic prostate cancer.

Methods: An indirect comparison of Overall Survival (OS) and time to PSA progression among abiraterone acetate, enzalutamide, cabazitaxel and Radium-223 was performed with a network metaanalysis. OS in the entire population of patients was the primary endpoint. OS in ECOG 0-1/2, BPISF≤ 4/>4, pretreated with 1 or 2 courses of chemotherapy, age≤65/>65 patients, patients with only bone metastases or bone and visceral metastases, and time to PSA progression were the secondary endpoints. An indirect comparison of the Hazard Ratio and the 95% Confidence Interval was performed, assuming an alpha error of 5% as an index of statistical significance. The among-the-trial heterogeneity was assessed using a qualitative methodological and clinical analysis.

Results: Four trials were selected. In three trials, the comparator was placebo, in one trial it was mitoxantrone, the effect of which in improving survival was considered negligible. No significant difference in OS among abiraterone acetate, enzalutamide, cabazitaxel and radium 223 was observed in neither the entire population nor all the subgroups of patients. Enzalutamide resulted significantly better than abiraterone acetate, cabazitaxel or radium-223 in time to PSA progression.

Conclusion: Since no significant difference in efficacy seems to exist between the four therapeutic options in the treatment of castration-resistant, docetaxel-resistant, metastatic prostate cancer, the safety of the treatment, patient’s compliance and costs should represent the criteria to guide clinicians’ choice in clinical practice.

Keywords: Abiraterone Acetate, cabazitaxel, castration-resistant metastatic disease, enzalutamide, prostate cancer, radium-223.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 01 August, 2018
Page: [226 - 237]
Pages: 12
DOI: 10.2174/1574887113666180404120540
Price: $65

Article Metrics

PDF: 86
PRC: 1